Mucins are high molecular weight glycoproteins which are heavily glycosylated with many carbohydrate side chains. In epithelial cancers such as colorectal cancer, both qualitative and quanti tative alterations in carbohydrate and polypeptide moieties of mucin glycoproteins occur. These changes in mucin glycoproteins are one of the most common phenotypic markers of colorectal carcino genesis and may play an important pathobiological role. The expression of some of the sialylated carbohydrate antigens appears to correlate with a poor prognosis and increased metastatic potential in colorectal cancer. The increased exposure of peptide epitopes of mucin glycoproteins in colorectal cancer appears to be due to either abnormal glycosylation and/or altered levels of mucin gene tran scription. In addition, dysregulation of tissue specific mucin genes occurs in colorectal cancers. This information is currently being exploited for further elucidation of the molecular mechanisms involved in carcinogenesis, tumor progression and metastasis, and the development of novel methods of colo rectal cancer diagnosis and therapy. (Keio J Med 47 (1): 10-18, March 1998) 
Introduction
It has long been known that one of the most common phenotypic changes in colonic neoplasia is a marked change in the glycosylation that occurs in colonocytes. In this review, the alter-ations in both the carbohydrate and polypeptide moi eties of mucin glycoproteins in colon cancer will be dis cussed first. Then, our recent work on the regulation of mucin genes in colon cancer will be presented, followed by a discussion of the possible role of mucin glycopro teins in colon cancer metastasis. Lastly, the potential clinical applications of mucin glycoproteins in the diag nosis and therapy of colon cancer will be discussed.
Biochemical Properties of Mucin Glycoproteins
Mucin glycoproteins consist of a protein backbone with many carbohydrate side chains of varying lengths, sequences, compositions and anomeric linkages. They have a very large molecular weight (400 to>1000kDa), many O-glycosidically linked carbohydrate side chains which may constitute 50-85% of the total molecular weight, a high content of serine, threonine and proline in the protein backbone structure, and a buoyant den sity much higher than non-glycosylated proteins (1.35 -1.50gcm-3) due to their high carbohydrate content.
The carbohydrate moieties of glycoproteins and gly colipids are capable of generation diverse recognition signals because of the variety of the type of sugars, diverse glycosidic and anomeric linkages, and also due to extensive branching. Because of structural diversity, carbohydrate containing molecules have been impli cated in many important biological functions of cells. These include receptor functions for growth factors, hormones, toxins, bacteria, and virus lectins, growth regulation, cellular differentiation, homotypic and het erotypic, cell-cell interactions, cell-substratum or cell basement membrane interactions and various immuno logical functions.1-4 In addition, carbohydrates contrib ute to the unique physiochemical properties of the molecules which provide a protective function for mucosal cells.
Recently, the structures of 9 human mucin poly peptide backbone structures have been identified using molecular cloning techniques.1 These mucin genes are expressed in a highly tissue and cell specific fashion and may be membrane associated or secreted. An example of membrane mucin is MUC1, which is highly expressed in normal mammary and pancreatic ductal cells (Fig  1) .1,9,11 It has a central tandem repeat region which is highly glycosylated with a transmembrane domain and a cytoplasmic tail which interacts with actin cytoskeletal components. An example of secretory mucin is MUC2, one of the major intestinal mucins (Fig 1) . MUC2 also has a central tandem repeat region which is more heavily glycosylated than that of MUCl.12,13 Furthermore, it has a high cysteine content in the non-repetitive regions fl anking the tandem repeats, which may be involved in polymerization into the large multimers characteristic of secretory mucins. MUC5AC and MUC6 are two gastric mucins, that we have recently cloned and sequenced, which have a structural motif similar to that of MUC2.14,19,20 These are normally expressed in the stomach but not in the colon.
Alteration of Mucin Glycoproteins in Colon Cancer
The changes in mucin glycoproteins that occur in gastrointestinal cancers may be broadly divided into two general types, aberrant glycosylation and altered Fig 1 Schematic drawing of MUC1 and MUC2 structure. MUC1 is a membrane mucin that is thought to protrude from the cell surface with a rigid but hydrophilic structure. It contains relatively short amino and carboxyl terminus domains. The trans membrane domain is found near the carboxyl termi nus. MUC2 is a secretory mucin. It has two internal repetitive domains that are rich in potential O-glyco sylation sites (Ser and Thr residues). The sequences with homology to vWF flank the internal glycosylated domains and comprise the majority of the amino and carboxyl termini. expression of mucin polypeptide epitopes (Table 1) . Aberrant glycosylation includes changes in the expres sion of core region carbohydrates which arise due mainly to incomplete synthesis, and of backbone region and peripheral region carbohydrates that occur mainly due to elongation and modification of existing struc tures. Thus, in colon cancer cells, the carbohydrate side chains of mucin glycoproteins may exhibit multiple cancer-associated carbohydrate antigenic epitopes in either the core region or the peripheral and backbone regions of the carbohydrate side chains. In cancer cells, altered expression of mucin polypeptide antigens occurs In addition, both sialyl Tn and extended sialyl Lex antigens may serve as prognostic markers.39-41 The primary tumors expressing these antigens have a worse prognosis than those with tumors that do not express them.
The changes in carbohydrate structures of mucin glycoproteins that occur in colon cancer cells may be summarized as follows. In normal mucin glycoprotein, the tandem repeats in the central tandem repeat region are heavily glycosylated, there are many carbohydrate side chains per molecule and each chain is long. With malignant transformation, the tandem repeats are more sparsely glycosylated, and carbohydrate chains may be much shorter and/or modified in the outer region. These changes may be due to altered carbohydrate metabolism or to changes in glycosyltransferases or in O-acetylation of sialic acids or to altered processing of mucin in cancer cells. Thus, the modified sugar struc tures, or exposed inner sugar core structures, or protein backbone moiety may serve as tumor markers and tumor vaccines and may also be involved in various biological properties of cancer.
Changes in the Mucin Polypeptide Backbone Structures
At least 9 different human mucin genes have been identified to date, MUC1 through MUC8 (there are two MUC5s-AC and B). The predominant structural feature of mucin is the central region consisting of repeat peptide sequences which become heavily glyco sylated. The tandem repeat units of each mucin gene have distinct amino acid sequences, but they all have a high content of threonine and/or serine, potential 0-glycosylation sites. Mucins are also expressed in an extremely tissue and cell specific fashion. For example , MUC2 and 3 are highly expressed in the intestine, while MUC5AC and 6 are highly expressed in normal stom ach but not expressed in normal intestine and colon .
The changes in the expression of mucin polypeptide antigens and in the regulation of mucin genes in colon cancer may be summarized as follows: 1) an increased expression of mucin peptide antigens (e. g. MUC1 and MUC2 in mucinous cancer) caused by either a) sparse glycosylation with increased exposure of peptide epi-topes, or b) incomplete glycosylation with increased ex posure of peptide epitopes or c) increased transcription of the mucin gene. 2) Decreased expression of mucin polypeptide antigens caused by decreased transcription of mucin genes (MUC2, MUC3), or. 3) De novo expres sion or inappropriate or ectopic expression of mucin peptides (e. g. MUC5AC, MUC6), caused by inappro priate or ectopic expression of mucin genes due to dys regulation. When the immunohistochemical expressions of MUC1, 2, and 3 peptide epitopes and mRNA levels were compared between normal and colon adeno carcinoma tissues using specific mucin peptide anti bodies and Northern blotting, increased expressions of MUC1, MUC2 and MUC3 mucin peptide epitopes were observed in colonic adenocarcinomas of all histological subtypes. In mucinous colon cancers, the expression of MUC2 mucin peptide epitopes was greatly increased. MUC2 mRNA levels were decreased in colonic adeno carcinoma as compared to normal colonic tissues while being increased in mucinous carcinoma.12. 43 When one considers the mRNA levels of colonic adenocarcinoma, the observed increases in MUC1, 2 and 3 mucin polypeptide expressions are likely due to decreased glycosylation. In mucinous cancers, increased expression of MUC2 mucin epitopes is likely due to upregulation of the MUC2 mucin gene. Interestingly, when the expressions of stomach associated MUC5 and MUC6 mucin polypeptide epitopes were examined in colonic adenocarcinomas, both mucin polypeptide epi topes which are not expressed in normal colonic mucosa were found to be expressed ectopically in most colon cancer patients.
In addition, a recent analysis of 5 year survival of patients with Dukes' B1, B2 and Cl colon cancer showed that all 10 patients with negative fundic mucin peptide expression and all 7 patients with negative MUC5 mucin peptide expression survived 5 years, while the patients with positive expression of these peptide antigens showed 65-70% 5 year survival. 40 This result indicates the expression of MUC5 and gas tric mucin peptide epitopes may serve as prognostic indicators.
Regulation of Mucin Genes in Colon Cancer
To date, only MUC1 and MUC2 promoters have been fully sequenced. The analysis of the promoter region of MUC2 indicates that immediately upstream from the cap site, the MUC2 promoter contains a TATA box and a CACCC box.44 Transient transfec tion experiments utilizing deletion constructs contain ing varying lengths of the promoter indicate that the CACCC box is important for MUC2 gene transcriptions. Electrophoretic mobility shift assay (EMSA) experi ments showed that Spl is capable of binding this motif.
In addition, this element appears to be able to bind other factors since only one band is supershifted with anti -Spl. The region between bases -171 and -228 may be important for specific expression from the MUC2 pro moter as it significantly enhances promoter activity in Cla colon cancer cells with a relatively high expression of MUC2. Recently, the importance of the 5' flanking region in goblet-cell-specific regulation has been postu lated for intestinal trefoil factor with the identification of so-called goblet cell response elements with a 9 base sequence in the intestinal trefoil factor promoter gene. The identical 9 base sequence, CCCCTCCCC, is pres ent between bases -289 and -299 of the MUC2 pro moter. We are currently examining the possible role of this sequence in goblet cell specific expression of the MUC2 gene. Our preliminary study indicates that possible mech anisms of upregulation of MUC2 mucin genes involve the signal transduction pathway involving Ras resulting in the activation of transcription factors NFkB and pos sibly Spl and other transcription factors which may bind to a positive regulatory element in the region -2864/ -1386 and possibly a CACCC box in the MUC2 pro moter. 45 We have also observed that a tumor promoter, TPA, upregulates MUC2 mRNA in colon cancer cells through the protein kinase C (PKC) pathway.46 How ever, the precise mechanism of activation and the tran scription factors involved in the activation by PKC pathways are not yet known.
In addition, our preliminary study indicates that hypermethylation of CpG islands in the MUC2 5' fl anking region may cause lower expression of the MUC2 gene while hypomethylation may cause upregu lation of the MUC2 mucin gene in colon cancer cells. However, we do not know whether this is a primary or secondary event.
The Role of Mucin Glycoproteins in Colon Cancer Metastasis
Cancer metastasis is a complex process consisting of a cascade of multiple, sequential, selective and inter dependent events. In colon cancer metastasis, the can cer cells must detach from the primary tumor, invade the entracellular matrix (ECM) and enter the circu lation, interact with lymphocytes and other blood com ponents, form multicellular aggregates and metastasize to preferential organ sites where they adhere to the capillary bed and, once access has been gained, cross the basement membranes as they extravasate to estab lish secondary parenchymal tumor foci by proliferation, induction of angiogenesis and evasion of host defense mechanisms.
There are several experimental models for studying each step in the metastatic cascade. In our study, we 
Potential Clinical Application
Potential clinical applications of cancer associated carbohydrate and peptide moieties of mucin glycopro teins in colorectal cancer are listed in Table 3 . Although high levels of mucin glycoprotein antigens (e. g. sialyl Lea, sialyl Lex, sialyl Tn, T, and MUC1 apomucin) are observed in the serum of patients with epithelial can cers, no mucin glycoprotein antigenic markers have yet been shown to be sensitive or specific enough to be clinically useful as diagnostic serological markers for cancers.1,7
Monoclonal antibodies against mucin-associated anti gens (sialyl Tn, T, Tn, sialyl Lex, Ley) may also be used for targeting radioisotopes (131I, 111In, 131Tc) for imag ing and therapy or for targeting cytotoxic drugs and and peptides in epi thelial cancer cells are being exploited for immuno histochemical diagnosis and prognostic assessment, serological detection, radioimmunolocalization and immunotherapy. The synthesis of cancer associated oli gosaccharides and polypeptide backbone structures or their mimetics as glycan interaction inhibitors or tumor vaccines may play an important role in the treatment of colorectal cancer. Thus, further elucidation of the structure, biology and molecular mechanisms involved in the regulation of the expression of cancer-associated mucin glycoproteins and the development of transgenic or knockout animals of mucin genes and/or glycosyl transferases will yield very important and useful data leading not only to furthering our knowledge of colo rectal carcinogenesis, but also to development of effec tive diagnostic and therapeutic methods for colorectal cancer. 
